Exploring avidity: Understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands

British Journal of Pharmacology

Volumn 168, Issue 8, 2013, Pages 1771-1785

  Vauquelin, Georges ^a   Charlton, Steven J ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

avidity; binding mechanism; bivalent ligand; drug design; pharmacodynamics; rebinding; residence time; simulations

Indexed keywords

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CALCULATION; CHEMICAL PHENOMENA; HALF LIFE TIME; LIGAND BINDING; MATHEMATICAL MODEL; PHARMACOPHORE; PRIORITY JOURNAL; SIMULATION; TARGET RESIDENCE TIME; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG DESIGN; ENZYME SPECIFICITY;

DRUG; LIGAND; PROTEIN BINDING;

ANTIBODY AFFINITY; BINDING SITES, ANTIBODY; COMPUTER SIMULATION; DRUG DESIGN; HALF-LIFE; LIGANDS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 84875459594     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12106     Document Type: Article

References (57)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, et al. (2009). Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23: 442-450.
3. Arranz-Plaza E, Tracy AS, Siriwardena A, Pierce JM, Boons G-J, (2002). High-avidity, low-affinity multivalent interactions and the block to polyspermy in Xenopus laevis. J Am Chem Soc 124: 13035-13046.
4. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI, (2008). Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14: 2171-2179.
5. Berg HC, Purcell EM, (1977). Physics of chemoreception. Biophys J 120: 193-219.
6. Christensen LLH, (1997). Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 249: 153-164.
7. Christopoulos A, (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210.
8. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
9. Coombs D, Goldstein B, (2004). Effects of geometry of the immunological synapse on the delivery of effector molecules. Biophys J 87: 2215-2220.
10. Copeland RA, (2012). Conformational adaptation in drug-target interactions and residence time. Future Med Chem 3: 1491-1501.
11. Copeland RA, Pompliano DL, Meek TD, (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.
12. De Meyts P, Roth J, Neville DM Jr, Gavin JR 3rd, Lesniak MA, (1973). Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun 55: 154-161.
13. De Meyts P, Bianco R, Roth J, (1977). Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 251: 1877-1888.
14. De Meyts P, Gauguin L, Manegold Svendsen A, Sarhan M, Knudsen L, Nohr J, et al. (2009). Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors. Ann N Y Acad Sci 1160: 45-53.
15. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, et al. (2006). Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49: 366-372.
16. Dwir O, Solomon A, Mangan S, Kansas GS, Schwarz US, Alon R, (2003). Avidity enhancement of L-selectin bonds by flow: shear-promoted rotation of leukocytes turn labile bonds into functional tethers. J Cell Biol 163: 649-659.
17. 1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol 367: 413-422.
18. Frost JJ, Wagner HR Jr, (1984). Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Res 305: 1-11.
19. Fujimori K, Covell DC, Fletcher JE, Weinstein JN, (1989). Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 49: 5656-5663.
20. Goldstein B, Dembo M, (1995). Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. Biophys J 68: 1222-1230.
21. Gregory P, Adams GP, Tai M-S, McCartney JE, Marks JD, Stafford WF III, (2006). Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 12: 1599-1605.
22. Holliger P, Hudson PJ, (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
23. Hrabctová S, Nicholson C, (2004). Contribution of dead-space microdomains to tortuosity of brain extracellular space. Neurochem Int 45: 467-477.
24. Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al. (2010). CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A 107: 20565-20570.
25. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van, Osdol W, et al. (1992). Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52: 5144-5153.
26. Kaufman EN, Jain RK, (1992). Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of a theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 52: 4157-4167.
27. Kenakin TP, (2009). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 8: 617-626.
28. Kramer RH, Karpen JW, (1998). Spanning biding sites on allosteric proteins with polymer-linked ligand dimers. Nature 395: 710-713.
29. Limbird LE, Lefkowitz RJ, (1976). Negative cooperativity among β-adrenergic receptors in frog erythrocyte membrane. J Biol Chem 251: 5007-5014.
30. Müller KM, Arndt KM, Plückthun A, (1998). Model and simulation of multivalent binding to fixed ligands. Anal Biochem 261: 149-158.
31. Pack P, Müller K, Zahn R, Plückthun A, (1995). Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol 246: 28-34.
32. 2L- receptor interactions in intact cells. Biochem Pharmacol 75: 2192-2203.
33. Perry DC, Mullis KB, Øie S, Sadée W, (1980). Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. Brain Res 199: 49-61.
34. Plückthun A, Pack P, (1997). New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3: 83-105.
35. Rudnick SI, Adams GP, (2009). Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 24: 155-161.
36. Schuck P, Minton AP, (1996). Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem 240: 262-272.
37. Shinohara Y, Hasegawa Y, Kaku H, Shibuya N, (1997). Elucidation of the mechanism enhancing the avidity of lectin with oligosaccharides on the solid phase surface. Glycobiology 7: 1201-1208.
38. Spivak CE, Oz M, Beglan CL, Shrager RI, (2006). Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: radioligand binding, confocal microscopy, and mathematical simulations. Cell Biochem Biophys 45: 43-58.
39. Steinfeld T, Mammen M, Smith JA, Wilson RD, Jasper JR, (2007). A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72: 291-302.
40. Steinfeld T, Hughes AD, Klein U, Smith JA, Mammen M, (2011). THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 79: 389-399.
41. Swinney DC, (2006). Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Discov 3: 569-574.
42. Swinney DC, (2008). Applications of binding kinetics to drug discovery: translation of binding mechanisms to clinically differentiated therapeutic responses. Int J Pharm Med 22: 23-34.
43. Swinney DC, (2009). The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12: 31-39.
44. 2-adrenoceptor agonist salmeterol. Br J Pharmacol 158: 183-194.
45. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ, (2001). Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248: 47-66.
46. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, Gales C, et al. (2005). Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J 24: 1954-1964.
47. Valant C, Lane JR, Sexton PM, Christopoulos A, (2012). The best of two worlds? Bitopic orthostetic/allosteric ligands of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 52: 153-178.
48. Vauquelin G, (2010). Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 5: 927-941.
49. Vauquelin G, Charlton S, (2010). Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488-508.
50. Vauquelin G, Packeu A, (2009). Ligands, their receptors and. plasma membranes. Mol Cell Endocrinol 311: 1-10.
51. 1 receptors and their non-peptide antagonists. Biochem Pharmacol 61: 277-284.
52. Weinstein JN, Eger RR, Covell DG, Black CDV, Mulshine J, Carrasquillo JA, et al. (1987). The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 507: 199-210.
53. 1 cannabinoid receptors in intact cells. Fundam Clin Pharmacol 25: 200-210.
54. Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, et al. (2004). Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 335: 49-56.
55. Zhang R, Monsma F, (2009). The importance of drug-target residence time. Curr Opin Drug Discov Devel 12: 488-496.
56. Zichi D, Eaton B, Singer B, Gold L, (2008). Proteomics and diagnostics: let's get specific, again. Curr Opin Chem Biol 12: 78-85.
57. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD, (2000). Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 60: 7008-7013.